Literature DB >> 5304832

Effects of triiodothyronine-induced hypermetabolism on factor 8 and fibrinogen in man.

J C Hoak, W R Wilson, E D Warner, E O Theilen, G L Fry, F L Benoit.   

Abstract

Triiodothyronine (liothyronine sodium) (400-500 mug/day for 14 days) was given to six normal subjects. Factor VIII (antihemophilic globulin) activity increased from 109 to 167% (P < 0.05); fibrinogen increased from 344 to 581 mg/100 ml (P < 0.01). To test whether the increases in factor VIII activity and fibrinogen were mediated by beta adrenergic receptors, propranolol (20 mg every 6 hr) was given orally to four other normal subjects in addition to triiodothyronine for 14 days. Factor VIII increased from 100 to 161%; fibrinogen increased from 374 to 564% (P < 0.01). Factor VIII activity did not change in a severe classical hemophiliac made hypermetabolic with triiodothyronine, but it increased from 39 to 82% in a patient with von Willebrand's disease. Triiodothyronine-induced hypermetabolism increased the incorporation of selenomethionine-(75)Se into plasma fibrinogen. These results suggest that the increases in clotting factor activity during triiodothyronine-induced hypermetabolism reflect an effect of increased protein synthesis rather than enhanced stimulation of beta adrenergic receptors.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5304832      PMCID: PMC322281          DOI: 10.1172/JCI106034

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  PHARMACODYNAMIC EFFECTS OF BETA-ADRENERGIC RECEPTOR BLOCKADE IN PATIENTS WITH HYPERTHYROIDISM.

Authors:  W R WILSON; E O THEILEN; F W FLETCHER
Journal:  J Clin Invest       Date:  1964-08       Impact factor: 14.808

2.  THE BIOLOGICAL DISAPPEARANCE RATE OF PROTHROMBIN, FACTORS VII, IX AND X FROM PLASMA IN HYPOTHYROIDISM, HYPERTHYROIDISM, AND DURING FEVER.

Authors:  E A LOELIGER; B VAN DER ESCH; M J MATTERN; H C HEMKER
Journal:  Thromb Diath Haemorrh       Date:  1964-01-01

3.  Antihemophilic A factor (factor VIII) and fibrinogen in human blood. A study on the question of a closer correlation between the levels of the two factors.

Authors:  O EGEBERG
Journal:  Scand J Clin Lab Invest       Date:  1962       Impact factor: 1.713

4.  Effect of variation in thyroid function on the pressor response to norepinephrine in man.

Authors:  R E SCHNECKLOTH; G S KURLAND; A S FREEDBERG
Journal:  Metabolism       Date:  1953-11       Impact factor: 8.694

5.  Effects of beta-adrenergic receptor blockade in normal subjects before, during, and after triiodothyronine-induced hypermetabolism.

Authors:  W R Wilson; E O Theilen; J H Hege; M R Valenca
Journal:  J Clin Invest       Date:  1966-07       Impact factor: 14.808

6.  The biological half-life of I-131 fibrinogen.

Authors:  H C Hart
Journal:  Thromb Diath Haemorrh Suppl       Date:  1965

7.  The effects of triiodothyronine on hemodynamic responses to epinephrine and norepinephrine in man.

Authors:  V S Aoki; W R Wilson; E O Theilen; W W Lukensmeyer; P E Leaverton
Journal:  J Pharmacol Exp Ther       Date:  1967-07       Impact factor: 4.030

8.  Role of the autonomic nervous system in the resting tachycardia of experimental hyperthyroidism.

Authors:  V J Cairoli; J R Crout
Journal:  J Pharmacol Exp Ther       Date:  1967-10       Impact factor: 4.030

9.  Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium.

Authors:  R A Buccino; J F Spann; P E Pool; E H Sonnenblick; E Braunwald
Journal:  J Clin Invest       Date:  1967-10       Impact factor: 14.808

10.  The rise in clotting factor 8 induced in man by adrenaline: effect of alpha- and beta-blockers.

Authors:  G I Ingram; R V Jones
Journal:  J Physiol       Date:  1966-11       Impact factor: 5.182

View more
  1 in total

1.  [Stress-metabolism after myocardial infarction-demonstrated by means of the behaviour of plasma proteins with short half-life (author's transl)].

Authors:  G Ollenschläger; H Gofferje; L Horbach; H Prestele; K Schultis
Journal:  Klin Wochenschr       Date:  1981-05-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.